Philanthropy re-visited: Merck’s focus on Africa
August 2018. In recent years Merck has been significantly stepping up its engagement in Sub-Saharan Africa. Focus on neglected tropical diseases or drug donation programs are but two building blocks. What other diseases are relevant? A conversation about a longer term strategy which aims at creating win-win results for regional healthcare systems, patients, Western pharma industry objectives, as well as Merck’s own profitability. Stefan Oschmann, Chairman of the Executive Board Merck KGaA answers B2Bioworld’s questions in direct conversation. Includes prospects of African scientists to participate in the company’s Future Insight Prize programme. In addition, B2Bioworld offers independent background to interested readers such as prevalence of neglected diseases in Africa, expropriation of German chemical companies in the U.S. during World War I, Pharma performance Access to Medicines, or name list of key participants to the London Declaration on Neglected Diseases 2012.Reading time: 12 min
Read Now: |
Other articles recommended
B2Bioworld offers you background information
Public-Private Partnership to Prevent Non-communicable Diseases
Merck Life Science: Make or Break Drug Discovery and Biopharma
Andrew Bulpin, Global Head of Merck Millipore Process Solutions on strategy, competitors, and the road ahead
Personalised Medicine: Let’s be clear what it means
Jonathan K.C. Knowles, at the time Head of Group Research Roche about his motivations, work in Roche, and competitors
Managers of Disease Meet Masters of Personal Health
Medical Innovation for Africa Only?
Book Review - open access
Roche Ethiopia: Build-up of an emerging market
Innovation – Try Again, Fail Again, Fail Better
Ulrich Betz, Vice President Department Head Innovation & Entrepreneurship Incubator; Merck Biopharma
Straight talking to MECA countries
Governance, anti-corruption, agriculture, digitization, citizen engagement, freedom of press, AMIS and Georgia